EGFR and non-small cell lung carcinoma: A phase I multicenter clinical trial (NCT0298110) has confirmed that almonertinib is safe, tolerable, and effective in patients with locally advanced or metastatic NSCLC with EGFR T790M mutation (Yang et al., 2020).